Evidence map›Paper›PMID 8294873›Full record

ArticleThe Journal of experimental medicine1994

Macrophage inflammatory protein 1 alpha, interleukin 3 and diffusible marrow stromal factors maintain human hematopoietic stem cells for at least eight weeks in vitro.

C M Verfaillie, P M Catanzarro, W N Li

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 131 citations in OpenAlex.

  1. Review
  2. Review
  3. Heparan sulfate proteoglycans: a GAGgle of skeletal-hematopoietic regulators.Developmental dynamics : an official publication of the American Association of Anatomists · 2008
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. HCC-1, a novel chemokine from human plasma.The Journal of experimental medicine · 1996
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

C M VerfaillieDepartment of Medicine, University of Minnesota, Minneapolis 55454.
P M Catanzarro
W N Li
University of Minnesota · US

Funding

RETROVIRAL TRANSDUCTION OF LYMPHOCYTES FOR ANTI-LYMPHOMA THERAPYP01CA021737 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, WESLEY J · 1985 to 1997
–
REGULATION OF HEMATOPOIESIS IN CML BY GAMMA INTERFERONR01CA045814 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MCGLAVE, PHILIP · 1987 to 1995
–
MINNESOTA FETAL TISSUE BANKR24HD030511 · NICHD · UNIVERSITY OF MINNESOTA TWIN CITIES · PI LOW, WALTER C · 1992 to 1992
–
NCI NIH HHS P01-CA-21737NCI NIH HHS R01-CA-4581401NICHD NIH HHS 1-R24-HD30511-01
6 · The paper itself

Abstract

Factors that induce proliferation of the human hematopoietic stem cell are ill-defined. Primitive hematopoietic progenitors can be maintained and differentiate in stroma-dependent, long-term bone marrow cultures (LTBMC), originally described by Dexter et al. (Dexter, T. M., L. H. Coutinho, E. Spooncer, C. M. Heyworth, C. P. Daniel, R. Schiro, J. Chang, and T. D. Allen. 1990. Molecular Control of Haemopoiesis). However, 70-80% of primitive progenitors capable of reinitiating secondary stromal cultures (LTBMC-initiating cells [IC]) are lost over a period of 5 wk in such cultures. We have recently described a novel "stroma-noncontact" culture system, in which hematopoietic progenitors are separated from the stromal layer by a 0.4-micron microporous filter membrane. Primitive progenitors in such cultures can not only differentiate into committed progenitors, but are also maintained to a greater extent than in "Dexter" cultures. However, still only 50% of the originally seeded LTBMC-IC are recovered at week 5. Since maintenance of primitive progenitors may depend not only on growth-promoting factors but also on factors that inhibit differentiation and/or proliferation, we evaluated the effect of macrophage inflammatory protein 1 alpha (MIP-1 alpha) or "stem cell inhibitor" in combination with the growth-inducing factor interleukin 3 (IL-3) on the recovery of LTBMC-IC from stroma-noncontact cultures. We demonstrate that addition of MIP-1 alpha alone to stroma-noncontact cultures does not change the number of LTBMC-IC present after 8 wk, indicating that this factor may not directly inhibit or stimulate proliferation of primitive progenitors. Addition of the growth stimulatory cytokine, IL-3, alone results in exhaustion of LTBMC-IC after 8 wk of culture, possibly as a result of their terminal differentiation. However, LTBMC-IC can be maintained for at least 8 wk when grown in stroma-noncontact cultures supplemented with both MIP-1 alpha plus IL-3. This effect depends on soluble (ill-defined) stromal factors, and results from a direct interaction of these cytokines with the progenitor population or its progeny, but not the stroma.

Indexed as

Bone MarrowBone Marrow CellsCell DivisionCells, CulturedChemokine CCL3Chemokine CCL4Culture MediaCytokinesFlow CytometryHematopoietic Stem CellsHumansInterleukin-3Macrophage Inflammatory ProteinsMonokinesStromal CellsChemokine CCL3Chemokine CCL4Culture MediaCytokinesInterleukin-3Macrophage Inflammatory ProteinsMonokines

Identifiers

PMID8294873
PMCPMC2191371
OpenAlexW2057878394

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.